Dr.seymour Butts Hemorrhoid Ointment
NDC Package 85248-018-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Dr.seymour Butts Hemorrhoid (lidocaine5% phenylephrine hcl 0.25% hemorrhoid) ointment is adults: When practical, cleanse the affected area with mild soap and warm water, rinse thoroughly, and gently dry. This formulation utilizes a ointment delivery system. Marketed by Jiangxi Yudexi Pharmaceutical Co., Ltd, this product is identified by NDC 85248-018 and is authorized under FDA application M015.

Identification & Billing

NDC Package Code
85248-018-01
Package Description
30 g in 1 TUBE
Product Code
11-Digit Billing Format
85248001801
RxNorm Crosswalk
  • RxCUI: 2672354 - lidocaine 5 % / phenylephrine HCl 0.25 % Rectal Ointment
  • RxCUI: 2672354 - lidocaine 0.05 MG/MG / phenylephrine hydrochloride 0.0025 MG/MG Rectal Ointment
  • RxCUI: 2672354 - lidocaine 5 % / phenylephrine hydrochloride 0.25 % Rectal Ointment

Clinical Specifications

Proprietary Name
Dr.seymour Butts Hemorrhoid
Non-Proprietary Name
Lidocaine5% Phenylephrine Hcl 0.25% Hemorrhoid
Substance Name
Lidocaine; Phenylephrine Hydrochloride
Dosage Form
Ointment - A semisolid3 dosage form, usually containing <20% water and volatiles5 and >50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Usage Information
Adults: When practical, cleanse the affected area with mild soap and warm water, rinse thoroughly, and gently dry. Apply to the affected area up to 4 times daily, especially at night, in the morning, and after each bowel movement. To use applicator: lubricate applicator; gently insert partway into the anal canal and apply a small amount. Clean applicator after each use. Children under 12 years of age: ask a doctor.

Regulatory & Marketing

Labeler Name
Jiangxi Yudexi Pharmaceutical Co., Ltd
Product Type
Human Otc Drug
FDA Application #
M015
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
01-29-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 85248-018-01 identifies a specific commercial package of 30 g in 1 tube of Dr.seymour Butts Hemorrhoid, a human over the counter drug labeled by Jiangxi Yudexi Pharmaceutical Co., Ltd. This ointment is formulated for topical use and contains lidocaine; phenylephrine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Jiangxi Yudexi Pharmaceutical Co., Ltd on January 29, 2026. The current certification is valid through December 31, 2027.

How is this Jiangxi Yudexi Pharmaceutical Co., Ltd product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 85248001801. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
85248-018-01
11-Digit CMS (5-4-2)
85248-0018-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.